Navigation Links
Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
Date:10/4/2007

MORRISTOWN, N.J., Oct. 4 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage, biopharmaceutical company, today announced that John Maki, President and Chief Executive Officer, will participate in two panel discussions titled "Outsourcing: Best Practices and Lessons Learned from an Industry Perspective" and "Exit Strategies: Managing Risk and Reward" at BIOTECH 2007 on Monday, October 8, 2007. The sessions will run from 9:00 a.m. to 10:15 a.m. ET and from 12:30 p.m. to 1:45 p.m. ET, respectively, at the Loews Hotel in Philadelphia, PA.

About BIOTECH 2007

BIOTECH 2007, which is hosted by the BioNJ and Pennsylvania Bio, is designed to enhance the growth and development of the bioscience industry in the New Jersey and Pennsylvania regions. It is an opportunity for entrepreneurs, researchers and executives of emerging and large companies to network and share ideas, strategies and experiences.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' strategy involves combining individual generic drugs that have previously received regulatory approval for other indications and thus have established post-marketing safety records. Vicus leverages its proprietary science to design and patent novel drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue. Vicus' development programs are powered by its network of leading clinical investigators and partners in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical development of Vicus' product candidates.

For additional information, go to the Company's website:

http://www.vicustherapeutics.com


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. State technology chief endorses IT audit recommendations
3. Fusion 2007: CA chief says IT complexity raises risk
4. Web-Based Learning Developed under new Chief Education Officer
5. Chemical-petroleum executive joins Virent Energy board
6. Visions: Matheys says CIO role is good training for executive suite
7. Biotech executive books a career flight thats closer to home
8. CEOs Gone Wild? Risks and rewards in the executive suite
9. Early-stage executives hear from investors
10. Pedlar the latest executive to leave Merge
11. Financial executives to launch Madison chapter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... to their offering. ... , An increasing ... anticipated. Nanotechnology will be applied at all stages of drug ... in clinical trials. Many of the assays based on nanobiotechnology ...
(Date:12/2/2016)... ... ... The Conference Forum has announced that the 3rd annual Immuno-Oncology 360° ... 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors Dr ... approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and scientific ...
(Date:12/2/2016)...   SurePure, Inc. (OTCQB: SURP) a global ... has concluded an agreement with Tamarack Biotics under which ... to acquire units of the Company,s patented photopurification technology ... Concurrently with the option, SurePure has ... will seek regulatory approvals in the United ...
(Date:11/30/2016)... New York , November 30, 2016 ... consolidated as a few players hold a dominant share ... Group, Charles River Laboratories International, Inc., and Merck KGaA, ... market in 2015. Transparency Market Research observes that these ... are focused on development products that are do not ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):